A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

HCC Clinical Trial

— YH001  

Official title:

An Open-Label, Non-Randomized, Multi-center Phase 2 Study of YH001 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) and Hepatocellular Carcinoma (HCC)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05212922
• Other study ID #: YH001004
• Status: Withdrawn
• Phase: Phase 2
• Start date: June 2023
• Est. completion date: March 2025

Study information

• Verified date: November 2022
• Source: Eucure (Beijing) Biopharma Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an Open-label, Non-Randomized, Multi-center Phase 2 study of YH001 in Combination with Toripalimab，The study is designed to determine the safety ，tolerability and antitumor activity of YH001 in combination with Toripalimab in subjects with advanced NSCLC and HCC.

Description:

This study will include two cohorts of up to 40 subjects each treated with RP2D dose YH001 in combination with 240 mg Toripalimab to assess the antitumor activity and safety/tolerability.

According to Simon's two stage design, in the first stage, 9-10 subjects will be accrued. If there are ≤ 1 subjects achieving an objective response, the futility stop will be called. Enrollment will start for the second stage after Stage 1 data pass futility test. In the second stage, 17-19 subjects will be enrolled to have 27 subjects in total. If there are ≥ 5 subjects achieving an objective response, a stop could be called for meeting the primary objective.

In all cohorts, 4 mg/kg or other higher dose level of YH001 (not exceeding MTD) may be needed based on the safety data in the first stage.

• Cohort A: YH001 in combination with Toripalimab in subjects with advanced PD-L1 positive NSCLC as 1st line treatment;

• Cohort B: YH001 in combination with Toripalimab in subjects with previously systemically treated advanced HCC as 2nd line treatment;

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female, aged = 18 years;

2. Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures.

3. Target Population

Cohort A:

• Have histologically or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous)

• Recurrent or unresectable locally advanced (Stage IIIB) or metastatic (Stage IV);

• Naïve to any systemic anti-cancer therapy

• No EGFR mutation or ALK/ ROS1 gene rearrangement

• PD-L1 positive (TPS=1%) NSCLC

Cohort B:

• HCC diagnosis confirmed by or radiology, histology, or cytology;

• Barcelona Clinic Liver Cancer (BCLC) Stage C or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy and not amenable to a curative treatment approach;

• Child-Pugh A liver score within 7 days prior to first dose of study drug;

• Documented objective radiographic progression during or after treatment with sorafenib/lenvatinib, or intolerant of sorafenib/lenvatinib; or documented objective radiographic progression during or after treatment with atezolizumab and bevacizumab, or intolerant of atezolizumab and bevacizumab.

4. At least 1 unidimensional measurable target lesion per RECIST v1.1

5. ECOG performance status score 0 or 1

6. Have life expectancy of at least 12 weeks based on investigator's judgement.

7. Adequate organ and bone marrow function:

8. Women of reproductive potential must have negative serum beta human chorionic gonadotropin (ß -HCG) pregnancy test within 7 days of the fist dose of YH001.

9. Women of reproductive potential who are sexually active with a non-sterilized male must consistently use highly effective contraception/birth control between signing of the informed consent and 120 days after the last administration of the study drug.

Exclusion Criteria:

1. Treatment with any investigational drug within 4 weeks prior to the fist dose of study drug;

2. Prior anticancer therapy:

• Cohort B: Subjects received sorafenib/lenvatinib within 14 days of first dose of study medication.

• Prior palliative radiotherapy to bone metastases = 2 weeks prior to the first dose of YH001 is acceptable.

• It is unacceptable to have wash out less than 2 weeks for herbal therapy approved for anticancer.

3. Subjects with prior anti-CTLA-4 checkpoint inhibitors should be excluded.

4. Subjects with a history of = Grade 3 immune-related adverse events resulted from previous immunotherapy or an AE of any grade that resulted in discontinuation of prior immunotherapy

5. History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis, or history of interstitial lung disease

6. Subjects requiring systemic treatment with corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive medications within 21 days before the planned first dose of study drug or has need to be treated while on trial

7. Allergic to YH001 and Toripalimab or any component of the study drug formulation.

8. Subjects with concomitant active autoimmune disease, history of autoimmune disease requiring systemic treatment, or history of autoimmune disease within the two years prior to study entry.

9. Primary central nervous system (CNS) malignancies or symptomatic CNS metastases.

10. Subjects with severe cardiovascular diseases, e.g. New York Heart Association (NYHA) Class III or IV heart failure, myocardial infection within 6 months prior to first dose of YH001, uncontrolled hypertension, unstable angina pectoris or unstable cardiac arrhythmia.

11. QTcF > 470 ms at baseline; no concomitant medications that would prolong the QT interval; no family history of long QT syndrome.

12. Viral infection:

• Acute or Chronic active Hepatitis B (HBsAg positive and HBV DNA=2000 IU/mL).

• Chronic HCV infection (HCV antibody positive and HCV RNA detectable).

• Human immunodeficiency virus (HIV) infection as well as COVID-19.

13. Subjects with active tuberculosis are excluded. Subjects who have received BCG vaccination may have a false positive PPD test. These subjects are eligible if they have a negative Interferon Gamma Release Assay (IGRA).

14. Clinically uncontrolled concurrent illnesses, including, but not limited to, active infection that requires systematic treatment, serious diabetes (fasting blood glucose > 250 mg/dl), psychiatric illness that would limit compliance with the study requirements and other serious medical illnesses requiring systemic therapies.

15. Continuance of toxicities due to prior radiotherapy or chemotherapy agents that have not recovered to = Grade 1 per CTCAE v5.0

16. Failure to recover adequately, as judged by the investigator, from prior surgical procedures; the subjects have had major surgery within 28 days, or minor surgery within 2 weeks prior to the first dose of YH001.

17. Subjects received any live or attenuated vaccine within 28 days prior to the first dosing of study drug. For inactivated or attenuated COVID -19 vaccine, follow local guidelines.

18. Pregnant or breast-feeding females.

19. Any clinically significant abnormality in the laboratory

20. Subjects have another active invasive malignancy within 5 years

21. Cohort B:

• History of esophageal or gastric variceal bleeding within the last 6 months, or current active gastrointestinal bleeding;

• Large tumor lesion in liver (=60% liver volum), portal vein invasion at the main portal branch (Vp4), inferior vena cava, or cardiac involvement of HCC based on imaging;

• Clinically diagnosed hepatic encephalopathy in the last 6 months

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• HCC
• NSCLC Stage IIIB
• NSCLC Stage IV

Intervention

Drug:
• YH001 + Toripalimab
YH001 + Toripalimab

Locations

Country	Name	City	State
Armenia	Gabrail Cancer Center Research	Canton	Ohio
Australia	Andrew Love Cancer Centre	Geelong	Victoria
Australia	University of New South Wales (UNSW) - Liverpool Hospital	Liverpool	New South Wales
Austria	Coffs Harbour Health Campus	Coffs Harbour	New South Wales
China	Beijing Cancer Hospital	Beijing	Beijing
China	Beijing Tsinghua Changgung Hospital	Beijing	Beijing
China	Bethune First Hospital Of Jilin University	Changchun	Jilin
China	West China Hospital of Sichuan University	Chengdu	Sichuan
China	Sir Run Run Shaw Hospital Zhejiang University School Of Medicine	Hangzhou	Zhejiang
China	The Affiliated Tumour Hospital of Harbin Medical University	Harbin	Heilongjiang
China	Nantong Tumor Hospital	Nantong	Jiangsu
China	Shanghai Pulmonary Hospital	Shanghai	Shanghai
China	Hubei Cancer Hospital	Wuhan	Hubei
China	Zhongnan Hospital of Wuhan University	Wuhan	Hubei
China	Henan Cancer Hospital	Zhengzhou	Henan
Taiwan	Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital	Kaohsiung
Taiwan	Kaohsiung Medical University - Chung-Ho Memorial Hospital	Kaohsiung
Taiwan	China Medical University Hospital	Taichung
Taiwan	Chi Mei Medical Center - Liouying	Tainan
Taiwan	Chi Mei Medical Center - YongKang	Tainan
Taiwan	Taipei Medical University Hospital	Taipei
Taiwan	Taipei Veterans General Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Eucure (Beijing) Biopharma Co., Ltd

Countries where clinical trial is conducted

Armenia,  Australia,  Austria,  China,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	trough concentration (Ctrough)	To characterize the pharmacokinetic (PK) profiles of YH001 in combination with Toripalimab	maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Other	terminal half-life (T1/2).	To characterize the pharmacokinetic (PK) profiles of YH001 in combination with Toripalimab	maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Other	Duration of response (DOR)	To assess other antitumor activity of YH001 in combination with Toripalimab by investigator's assessment according to the RECIST v1.1	maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Other	progression free survival (PFS)	To assess other antitumor activity of YH001 in combination with Toripalimab by investigator's assessment according to the RECIST v1.1	maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Other	time to response (TTR)	To assess other antitumor activity of YH001 in combination with Toripalimab by investigator's assessment according to the RECIST v1.1	maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Primary	ORR	Overall Response Rate (ORR) by investigator's assessment according to the RECIST v1.1	maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Secondary	safety and tolerability	The safety and tolerability will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0	maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Secondary	OS	To assess other antitumor activity of YH001 in combination with Toripalimab	maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Secondary	anti-drug antibodies (ADA)	Immunogenicity	maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Secondary	neutralizing antibodies (NAbs).	To assess the immunogenicity of YH001 in combination with Toripalimab	maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Secondary	peak concentration (Cmax)	To characterize the pharmacokinetic (PK) profiles of YH001 in combination with Toripalimab	maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.